Home・Lista de Ações・Exelixis Inc

Exelixis Inc

Fechado

SetorSaúde

50.59 0.56

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

50.18

Máximo

51.47

Indicadores-chave
By Trading Economics
Rendimento	1.6M 212M
Vendas	18M 629M
P/E Médio do Setor	16.654 57.002
EPS	0.82
Margem de lucro	33.729
Funcionários	1,077
EBITDA	-12M 263M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+0.82% upside

Dividendos
By Acuity
Próximos Ganhos	3 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-717M 13B
Abertura anterior	50.03
Fecho anterior	50.59

Sentimento de Notícias

By Acuity

50%

152 / 340 Ranking em Healthcare

Exelixis Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de ago. de 2026, 19:51 UTC

News

Exelixis Inc shares are lower amid an investigation for potential securities law violations and a revenue shortfall of $628.7 million in Q2.

11 de ago. de 2026, 23:51 UTC

Exelixis Inc shares are lower in after-market hours, continuing a downward trend since Tuesday's close amid notable volatility and market anticipation of the CPI report.

10 de ago. de 2026, 23:01 UTC

News

Exelixis shares are lower in after-market trading amid scrutiny over a potential securities fraud investigation and lowered full-year revenue guidance.

8 de ago. de 2026, 00:01 UTC

Exelixis Inc shares are trading lower in after-market hours, amid weak overall market conditions and unusual trading patterns.

7 de ago. de 2026, 21:01 UTC

Exelixis Inc shares are lower in after-market trading, reflecting notable weakness and remaining below the 20-day moving average. No specific news was identified.

6 de ago. de 2026, 23:31 UTC

Exelixis Inc's shares are higher in after-market hours, recovering from an earlier dip. The stock remains below its 20-day moving average.

5 de ago. de 2026, 23:02 UTC

News

Exelixis Inc. shares are lower in after-market trading following second-quarter results that missed revenue expectations and a cut to full-year guidance.

4 de ago. de 2026, 19:16 UTC

Exelixis Inc shares are higher today, reaching a peak above Monday's close. The broader market is supported by a drop in crude oil prices.

3 de ago. de 2026, 23:02 UTC

Exelixis Inc shares are lower in after-market trading, continuing a decline since Monday's close amid no specific news to explain the movement.

31 de jul. de 2026, 23:36 UTC

Exelixis Inc shares are lower in after-market trading, influenced by broader market weakness amid a decline in Apple shares following disappointing guidance.

30 de jul. de 2026, 17:56 UTC

Exelixis shares are higher during Thursday's session, gradually improving from an early dip. No specific company news was identified to explain the movement.

29 de jul. de 2026, 19:37 UTC

Exelixis Inc. shares are trading lower today amid high volume and broader market dynamics, including a significant surge in oil prices raising inflation concerns.

28 de jul. de 2026, 20:06 UTC

Exelixis Inc is trading higher amid a strong Biotechnology sector. The stock remains above its 20-day moving average, indicating market strength.

27 de jul. de 2026, 18:46 UTC

Exelixis Inc shares are higher today, reflecting broader market trends amid a notable decline in crude oil prices. The stock peaked earlier in the session.

24 de jul. de 2026, 19:46 UTC

Exelixis Inc shares are lower today, continuing a decline since Thursday. Broader market volatility is influenced by fluctuations in oil prices and U.S. tariffs.

22 de jul. de 2026, 21:26 UTC

News

Exelixis Inc will release its Q2 2026 financial results on August 5. Shares are trading higher after the announcement, reflecting positive investor sentiment.

Comparação entre Pares

Variação de preço

Exelixis Inc Previsão

Preço-alvo

By TipRanks

0.82% parte superior

Previsão para 12 meses

Média 51.75 USD 0.82%

Máximo 64 USD

Mínimo 41 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Exelixis Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para Exelixis Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

152 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.